Detalles de la búsqueda
1.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Cardiovasc Diabetol
; 22(1): 233, 2023 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37653496
2.
High levels of lipoprotein(a) - assessment and treatment. / Høyt nivå av lipoprotein(a) utredning og behandling.
Tidsskr Nor Laegeforen
; 142(1)2023 01 17.
Artículo
en Inglés, Nor
| MEDLINE | ID: mdl-36655975
3.
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.
Cardiovasc Drugs Ther
; 34(4): 515-523, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32363493
4.
Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
Circulation
; 136(4): 359-366, 2017 Jul 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28592434
5.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
N Engl J Med
; 372(16): 1489-99, 2015 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25773378
6.
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.
Heart Fail Rev
; 23(3): 303-323, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29516230
7.
[Correction: High levels of lipoprotein(a) assessment and treatment]. / Rettelse: Høyt nivå av lipoprotein(a) utredning og behandling.
Tidsskr Nor Laegeforen
; 143(2)2023 01 31.
Artículo
en Nor
| MEDLINE | ID: mdl-36718898
8.
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Lancet
; 385(9965): 331-40, 2015 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-25282519
9.
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet
; 385(9983): 2153-61, 2015 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25743173
10.
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
Eur Heart J
; 36(43): 2996-3003, 2015 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26330422
11.
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Circulation
; 129(2): 234-43, 2014 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-24255061
12.
Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk.
J Pediatr
; 167(2): 338-43.e5, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26059337
13.
Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)".
Circulation
; 137(6): 641-642, 2018 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29431667
14.
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
Cardiovasc Drugs Ther
; 28(3): 281-9, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24842558
15.
Response to the editor.
Heart Fail Rev
; 2018 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29968222
16.
Author's response to: letter to the editor.
Heart Fail Rev
; 23(5): 819, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30043131
17.
No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy.
Scand Cardiovasc J
; 47(2): 80-7, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23301875
18.
Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: Novel data using repeated measurements during 12-years follow-up.
Atheroscler Plus
; 51: 28-34, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36911286
19.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Diabetes Metab
; 49(2): 101418, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36608816
20.
Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.
Eur Heart J
; 37(17): 1357-9, 2016 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27026748